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Background: According to the World Health Organization, South Africa ranks as one of the highest burden of TB,
TB/HIV co-infection, and drug-resistant TB (DR-TB) countries. DR-TB treatment is complicated to administer and relies
on the use of multiple toxic drugs, with potential for severe adverse drug reactions. We report the occurrence of
adverse events (AEs) during a standardised DR-TB treatment regimen at two outpatient, decentralized, public-sector
sites in Johannesburg, South Africa.
Methods: We reviewed medical records of the six-month intensive treatment phase for rifampicin-resistant (RR) TB
patients registered May 2012 - December 2014. Patients contributed follow-up time until death, loss from treatment,
censoring (6 months) or data extraction. A standardized regimen of kanamycin, moxifloxacin, ethionamide, terizidone,
and pyrazinamide was used according to national guidelines. AEs were graded using the AIDS Clinical Trial Group
scale. We present subhazard ratios from competing risk analysis for time to severe AE, accounting for mortality and loss
from treatment.
Results: Across the two sites, 578 eligible patient files were reviewed. 36.7 % were categorized as low weight (≤50 kg)
at DR-TB initiation. 76.0 % had no history of TB treatment prior to the current episode of RR TB. 26.8 % were diagnosed
with RR TB while hospitalized, indicating poor clinical condition. 82.5 % of patients were also HIV positive, of whom 43.
8 % were on ART prior to RR TB treatment and 32.1 % initiated ART with or after RR TB treatment. Median CD4 count
was 114.5 (IQR: 45-246.5). Overall, 578 reports of AEs were captured for 204 patients (35.3 %) and 110 patients (19.0 %)
had at least one severe AE reported. Patients with at least one AE experienced a median of 3 (IQR: 2-4) AEs per patient.
HIV-positive patients with CD4 counts ≤100 cells/mm3 and those newly initiating ART were more likely to experience a
severe AE (sHR: 2.76, 95 % CI: 1.30–5.84 and sHR: 3.07, 95 % CI: 1.46–6.46, respectively).
Conclusion: Severe AE are common during the first 6 months of RR TB treatment and HIV-positive patients newly
initiating ART have the highest subdistribution hazard ratio for severe AE, accounting for the competing risks of death
and loss from treatment.
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South Africa has made progress in controlling the TB
epidemic; the 2015 Global Tuberculosis Report high-
lights a declining incidence and prevalence of TB for
South Africa [1]. Despite the progress seen tuberculosis
has been the most common cause of death in South Africa
from 2005 to 2014 [2] and the number of persons diag-
nosed with drug-resistant (DR-TB) TB has increased
significantly over the last decade from 2000 patients in
2005 to 18,734 in 2014 [1].
In 2011, South Africa adopted a policy of universal ri-
fampicin (RIF) resistance testing using Xpert MTB/RIF
(Cepheid, USA) as the first-line TB diagnostic in the
country. Reporting of DR-TB now focuses on RIF resist-
ant TB (RR TB), which includes RIF resistance with un-
known or pending sensitivities to other drugs, mono-RIF
resistant TB, multi-drug resistant (MDR) TB that is re-
sistant to both RIF and isoniazid (INH), extensively drug
resistant (XDR) TB which is MDR TB plus resistance to
second-line drugs from the fluoroquinolone and inject-
able aminoglycoside or cyclic peptide classes, or preXDR
TB which is MDR TB plus resistance to either a fluoro-
quinolone or a second-line injectable drug [3]. The
South African National TB Programme (NTP) treatment
guidelines for RR-TB indicate 18‐24 months of treatment
[4]. All RR TB patients are started on the standardized
second-line MDR TB regimen until further resistance is
either confirmed or ruled-out at which point the patient
may be switched to an individualized second-line TB
regimen (if preXDR or XDR TB) or INH may be added
to the regimen (if mono-RIF resistant) [4].
Second‐line TB treatment is complicated to administer,
with frequent and potentially severe adverse drug reac-
tions (ADR) [5, 6]. Adding to the complexity of treat-
ment, an estimated 60 % of all TB patients [1] and up to
80 % of RR-TB patients in South Africa [7] are also HIV-
infected and therefore eligible for antiretroviral therapy
(ART). RR TB treatment and ART present overlapping
toxicities which may be worsened by concomitant use,
for example both kanamycin and tenofovir may cause
renal dysfunction [8].
ADR can negatively impact the effectiveness of RR TB
treatment in many ways. Patients or clinicians may inter-
rupt, reduce dosage, or stop treatment in an attempt to al-
leviate side effects. This results in an increased risk of
acquiring additional drug resistance, failing treatment, or
dying from TB. ADR themselves may also result in
hospitalization, permanent disability, or death. Only 49 %
of the 2012 cohort of MDR TB patients in South Africa
were cured or successfully completed treatment, below
both the global average (50 %) and targets (75 %) [1].
Thus, evidence of the burden and risks of ADR during RR
TB treatment is important for both patients and clinicians
to manage this complexity. In order to quantify theburden of ADR during outpatient RR TB treatment in the
context of high co-infection with HIV, we present the re-
sults of a medical file review of routinely reported adverse
events (AE) from two decentralised public-sector sites
within South Africa.
Methods
The study was conducted at the TB Focal Point clinics at
Helen Joseph and Charlotte Maxeke Academic Hospitals
in Johannesburg, South Africa. Patients with laboratory
diagnosis of pulmonary or extrapulmonary RR TB from
any level of health facility in the catchment area are re-
ferred to these NGO-supported, outpatient, public-sector
facilities for initiation of second-line TB treatment and
further drug resistance testing. Patients are referred from
surrounding primary health care centres, private facilities,
Helen Joseph and Charlotte Maxeke inpatient wards, and
surrounding hospitals. A census of medical files for pa-
tients who enrolled for second-line TB treatment at Helen
Joseph (May 2012 to June 2014) or Charlotte Maxeke
(May 2012 to December 2014) were reviewed retrospect-
ively in September 2014 and April 2015, respectively. Only
patients with documentation of at least rifampicin resist-
ance, i.e. RIF resistance detected by Xpert, RIF mono-
resistance, MDR-TB diagnosed by LPA, or XDR TB were
included in the study.
Standard of care treatment
Upon referral the patient undergoes HIV counselling
and testing, patients are educated about the length and
toxicities of RR TB treatment, and informed about the
importance of screening exposed family members. Pa-
tients are then examined and evaluated by a medical of-
ficer. All RIF resistance diagnosed by Xpert is treated
presumptively as MDR TB as per the South African
National TB Programme (NTP) guidelines [4]. The in-
tensive phase of treatment (approximately 6 months)
consists of a five-drug regimen including the second-line
injectable kanamycin, moxifloxacin, ethionamide, terizi-
done, and pyrazinamide [4, 9]. The continuation phase
of treatment (18 to 24 months) includes moxifloxacin,
ethionamide, terizidone, and pyrazinamide. Treatment
dose is adjusted for patient weight, with patients 33 to
50 kg receiving smaller doses of kanamycin (500–750 mg
vs. 1000 mg), ethionamide (500 mg vs. 750 mg), and pyra-
zinamide (1000–1750 mg vs. 2000–2500 mg) than pa-
tients weighing 51 to 70 kg [4]. Linezolid and bedaquiline
were not available at the study sites during the study
period [10].
The 2010 South African ART guidelines indicated eligi-
bility for HIV-infected patients with TB co-infection at
CD4 ≤ 350 cells mm3 and for any patient with CD4 ≤ 200
cells mm3 [11]. Eligibility was expanded in 2013 to include
all patients with CD4 count ≤350 cells mm3 [12]. Thus, all
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TB site. Patients currently on ART can receive ART from
the RR TB site for the duration of second-line TB treat-
ment. From 2010, most South African ART patients in
the public sector are initiated on a standard, first-line
three-drug regimen of tenofovir, efavirenz or nevira-
pine, and lamivudine or emtricitabine. From 2013, a
fixed-dose combination of tenofovir, efavirenz, and
emtricitabine has been the preferred first-line ART
regimen [12].
Patients are asked to return at two weeks and subse-
quently reviewed monthly by a TB nurse or medical offi-
cer for adherence to therapy, evaluation of side effects
and treatment response. Sputum samples for smear mi-
croscopy and TB culture are collected monthly in pul-
monary TB patients to assess for sputum smear and
culture conversion. As per NTP treatment guidelines,
baseline laboratory tests are conducted prior to treat-
ment initiation to assess for anaemia and renal, thyroid
and liver function. If HIV co-infected, laboratory tests to
monitor HIV treatment (CD4 count and HIV viral load)
or ART toxicities are integrated. Every two months dur-
ing the six-month intensive phase of treatment blood
work is repeated. Additional or more frequent laboratory
testing may be ordered if clinically indicated. Audiology
testing for hearing loss is conducted monthly during the
six month intensive phase due to the high rates of ami-
noglycoside induced hearing dysfunction [13]. Electro-
cardiograms for monitoring were not included in the
guidelines for the standard RR TB regimen at the time
of the study.
Adverse events and drug reactions
For most of the period under review, pharmacovigilance
requirements were for targeted spontaneous reporting to
the national regulatory agency, the Medicines Control
Council. Programmatic pharmacovigilance for HIV and
TB, including RR TB was in the process of being rolled
out by the National Pharmacovigilance Centre [14]. Ac-
cording to the regulatory form which is separate from
the medical file, ‘advice about voluntary reporting’ re-
quests clinicians to please report all ‘serious reactions
and interactions with all products’ to the Medicines
Control Council.
Most of the AEs identified in this file review were found
in the clinical progress notes section of the medical files.
Causality was not routinely documented. AEs such as
weight loss could be related to adverse drug reactions
from second-line TB treatment or ART, or HIV or TB
morbidity. Pre-existing conditions at the time of RR TB
treatment initiation were noted under patient medical his-
tory and co-morbidities and therefore not included in the
adverse events. However, if pre-existing conditions wors-
ened during treatment it would be reported.AEs of interest were those most likely to be adverse
drug reactions and defined prior to the review as including
renal dysfunction, hypokalaemia, ototoxicity, vestibular
dysfunction, severe anaemia, psychosis and depression,
peripheral neuropathy, seizures, hypothyroidism, nausea
and/or vomiting, and joint pain. Other AEs identified
during the review were recorded and categorized during
data analysis. Standard of care does not include routine
screening for gastro-intestinal disorders such as nausea or
vomiting or mental health such as depression, or insom-
nia; AEs captured were as reported by patients during
routine visits.
AEs were graded either at the time of the event (in the
clinical notes) or during the file review by the treating
clinician as mild (grade 1), moderate (grade 2), severe
(grade 3), potentially life-threatening (grade 4), or fatal
(grade 5) according to the AIDS Clinical Trials Group
grading system [15]. AEs included those detected clinically
and through laboratory testing. Where outcome of the AE
(e.g. death, hospitalization, permanent disability, drug dis-
continuation, and/or drug dose reduction) was available in
the file it was also captured. Deaths that were not reported
as an outcome of an AE, i.e. those thought to be from TB,
were not re-categorised as an AE.
Statistical analysis
We present descriptive analysis of the number of AEs by
patient, types of AE reported, and severity of AEs identi-
fied from the medical record review, including frequen-
cies and proportions.
We used time to event analysis to present the mean
time from second-line TB treatment initiation to (first)
severe adverse event (grade 3 or higher). Follow-up is
censored at 6 months after second-line TB treatment
initiation, final outcome (i.e. death or loss from treat-
ment for at least 2 months), transfer to another site, or
data extraction (September 2014 for Helen Joseph and
April 2015 for Charlotte Maxeke).
We used competing risk regression method from Fine
and Gray [16] to determine if occurrence of a severe AE
was associated with a priori identified patient demo-
graphic and clinical characteristics. In time-to-event ana-
lysis, an individual can either experience the event of
interest or be censored. However, in real life, an individ-
ual may experience a number of negative outcomes, not
only the event of interest. Occurrence of one negative
outcome means that the other negative outcomes cannot
occur, and only the time to failure for the earliest event
is observed. The method of competing risk regression
was chosen because of the high rate of mortality and loss
from treatment in South African RR TB cohorts; one of
these poor outcomes could occur before the severe AE
and therefore the severe AE would not occur (or would
occur but never be documented). Because loss from
Table 1 Characteristics of patients at initiation of second-line TB
treatment (n = 578)
Characteristic Description Count Proportion
Sex Male 283 49.0 %
Female 295 51.0 %
Age 10–24 years 56 9.7 %
25–39 years 338 58.5 %
40–54 years 163 28.2 %
55+ years 21 3.6 %
Weight (kg) Low weight (≤50 kg) 195 36.7 %
>51 kg 337 63.3 %
Missing 46 8.0 %
TB foci Pulmonary 541 93.6 %
Extrapulmonary only 37 6.4 %
Prior TB No history of TB treatment 439 76.0 %
Prior first-line TB treatment 119 20.6 %
Prior TB treatment with
streptomycin
7 1.2 %
Unknown 13 2.2 %
Current TB diagnosis MDR-TB (INH and RIF
resistance)
182 31.5 %
RIF mono-resistant TB 198 34.3 %
RIF resistant, sensitivities
unknown
191 33.0 %
XDR TB (second-line
resistance)
7 1.2 %
Presenting symptoms Cough 281 65.9 %
Any of cough, weight loss,
fever, night sweats
453 78.4 %
Sputum smear
microscopy
Positive (scanty or higher) 284 49.1 %
Negative or unknown 294 50.9 %
Level of care at TB
diagnosis
Outpatient, ambulatory 406 70.2 %
Inpatient, hospitalized 155 26.8 %
Missing 17 2.9 %
MDR-TB multi-drug resistant tuberculosis, RIF rifampicin, INH isoniazid, XDR TB
extensively drug-resistant tuberculosis
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death and loss from treatment were considered to be the
risks competing with report of a severe AE. Univariate
(crude) subdistribution hazard ratios (sHR) with 95 %
confidence intervals (CI) are presented. All analysis was
completed in Stata v14 (College Station, TX).
Characteristics considered included: HIV status (HIV
negative, HIV-positive on ART prior to RR TB diagnosis
and initiation defined as at least 30 days prior to RR TB
treatment start, HIV-positive initiated on ART at or after
RR TB initiation, or HIV positive not on ART or ART
unknown); age category (10–24, 25–39, 40–54, 55 years
or older), and sex. We also examined TB symptoms (re-
port of cough, fever, weight loss, or night sweats), and
markers of severity of illness: low weight at treatment
initiation (≤50 kg) or diagnosed with RR TB during
hospitalization for any cause. CD4 count at RR TB treat-
ment initiation as documented in the patient file (HIV
negative, HIV-positive with CD4 > 100 cells/ mm3, or
HIV-positive with CD4 ≤ 100 cells/mm3) was defined as
the CD4 count measured up to 6 months prior or within
the first month of treatment. Information on pre-existing
conditions or self-reports of prior TB treatment (none,
first-line regimen, or regimen that included streptomycin)
were also considered. No patients reported having been
previously treated for RR TB. All patients were on stan-
dardized treatment regimens for RR TB; patients diag-
nosed with XDR TB were transferred out to initiate
individualized treatment at another site and therefore ex-
posure was censored.
Results
Across the two sites, 578 files were available for review
and patients eligible for the study, patient characteristics
are reported in Table 1. Patients presented with RR TB at
a median age of 35 (IQR: 29–42 years) and 49.0 % were
male. One-third of the patients (36.7 %) were categorized
as low weight (≤50 kg) at initiation of second-line TB
treatment, the median weight at initiation was 54 kg (IQR:
47.9–61.5). Only 1.2 % reported a history of TB treatment
with an injectable drug (streptomycin) and the majority
(76.0 %) had no history of any TB treatment prior to the
current episode of RR TB. Approximately one-quarter
(26.8 %) of the patients were diagnosed with RR TB while
hospitalized, indicating poor clinical condition.
HIV infection was the most common co-morbidity re-
ported as 82.5 % (n = 477/578) were HIV positive
(Table 2). Of those who were HIV positive, 43.8 % were
on ART at least 30 days prior to RR TB treatment initi-
ation with a median 332 days on ART (IQR: 160, 991)
and 31.9 % initiated ART with or after RR TB treatment
with a median time to ART initiation of 26 days after RR
TB treatment (IQR: 14, 42). Of the 77.8 % of HIV-
positive patients with CD4 counts reported at RR TBtreatment initiation, the median CD4 was 114.5 (IQR:
45-246.5). Half (50.2 %) were on the standard first-line
regimen for the public sector ART program (tenofovir,
efavirenz, and lamivudine or emtricitabine). Few other
co-morbidities were reported, with no one co-morbidity
affecting 10 or more patients. Diabetes mellitus (1.9 %),
renal insufficiency (1.4 %), and hepatitis or liver dys-
function (1.2 %) were the three most common co-
morbidities other than HIV. Seven women (2.4 % of
women) were pregnant during RR TB treatment.
Adverse events
Overall, 578 reports of AEs were captured for 204 pa-
tients (35.3 %) and 110 patients (19.0 %) had at least one
Table 2 Co-morbidities, clinical conditions and chronic
medications (n = 578)
Characteristic Description Count Proportion
HIV status Negative 95 16.4 %
Positive 477 82.5 %
Unknown 6 1.0 %
CD4 counta (n = 477) Low (≤100 cells/mm3) 173 36.3 %
>100 cells/mm3 198 41.5 %
Missing 106 22.2 %
ART status (n = 477) Not on ART 116 24.3 %
Median CD4 count 156.5 IQR: 65, 255
Initiated ART with or
after RR TB
153 32.1 %
Median CD4 count 100.5 IQR: 42.5, 221.5
Median days RR TB at
ART initiation
26 IQR: 14, 42
On ART prior to RR TB
initiation
209 43.8 %
Median CD4 count 101 IQR: 41, 253
Median days on ART at
RR TB initiation
332 IQR: 160, 991
ART regimen (n = 362) TDF + 3TC or ETC + EFV 182 50.23 %
D4T or AZT + 3TC + EFV 34 9.4 %
TDF + 3TC + LPV/r 3 0.8 %
D4T or AZT + 3TC + LPV/r 46 12.7 %
Other regimen 53 14.6 %
Missing 44 12.2 %
Reported co-morbidities Hepatitis or liver
disorder
7 1.2 %
Epilepsy 6 1.0 %
Psychiatric disorder 5 0.9 %
Diabetes mellitus 9 1.6 %
Renal dysfunction 8 1.4 %
Pregnancy (n = 295) Pregnant 7 2.4 %
Contraception (n= 295) Using hormonal
contraceptive
16 5.4 %
ART antiretroviral therapy, TDF tenofovir, 3TC lamivudine, EFV efavirenz,
LPV/r lopinavir/ritonavir
aCD4 count at RR TB treatment initiation
Fig. 1 Counts of most frequent mild or moderate adverse events by
HIV and ART status (n = 204)
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AE experienced a median of 3 AEs (IQR: 2–4) per
patient.
Gastro-intestinal AEs were the most common, with
138 reports of vomiting, nausea, abdominal pain, epi-
gastric discomfort, diarrhoea, constipation, loss of appe-
tite, or weight loss. Although most nausea and vomiting
reported (67.1 % of 70 reports) was mild to moderate
(Fig. 1), it was the second most commonly reported se-
vere AEs (11.8 % of all the severe AEs). The most com-
mon severe AE reported was hearing loss or ototoxicity
(Fig. 2). In total, 114 reports of hearing loss were notedaffecting 17.3 % of patients (n = 100/578). Of the hearing
loss AEs reported, 61 (53.5 %) were categorised as grade
3+. Renal dysfunction or failure accounted for 10.3 % of
all severe AEs, with 20 episodes reported. Psychosis
(6.7 %), neuropathy (6.1 %) and hepatitis or liver dys-
function (5.6 %) were also among the most frequent se-
vere AEs reported. Rare severe AE reports included deep
vein thrombosis (n = 2), sepsis (n = 1), miscarriage (n = 1),
suicidal thoughts (n = 1), and neuroleptic malignant syn-
drome (n = 1).
Kanamycin was listed as the suspected drug causing
AE or severe AE for 54.4 % (111/204) of patients experi-
encing an AE. Among the 309 AEs with at least one sus-
pected drug listed, kanamycin was listed 175 times
(56.6 %). Of the severe AEs with at least one suspected
drug listed, terizidone was listed 32/126 times (25.4 %).
Less than 5 % (n = 26) of the AEs had hospitalization doc-
umented as an outcome of the AE. Nearly 20 % (n = 109)
of identified AEs resulted in the suspected drug being dis-
continued and an additional 10 % (n = 57) resulted in the
dose of the suspected drug being reduced.
Subdistribution hazard ratios of severe AE
Of the 578 patient files reviewed, 18 did not contribute
to the time-to-event analysis as patient either died or
were transferred out prior to returning to the clinic after
Fig. 2 Counts of most frequent severe adverse events by HIV and
ART status (n = 110)
Table 3 Risks of severe (grade 3+) adverse events during first
6 months of RR TB treatment
Characteristic Description sHRa 95 % CI
Age category 10–24 years 0.70 0.31–1.58
25–39 years Referent
40–54 years 0.92 0.61–1.39
55 years + 1.93 0.85–4.37
HIV and CD4 status HIV negative Referent
HIV+, CD4 > 100 cells/mm3 1.81 0.84–3.89
HIV+, CD4 ≤ 100 cells/mm3 2.76 1.30–5.84
HIV and ART status HIV negative Referent
HIV+, initiated ART prior to RR TB 1.77 0.83–3.77
HIV+, initiated ART with or after RR TB 3.07 1.46–6.46
HIV+, not on ART 1.15 0.43–3.10
Weight (kg) Weight >51 kg Referent
Low weight (≤50 kg) 1.43 0.97–2.10
Prior TB treatment No TB history reported Referent
History of first-line TB treatment 1.33 0.85–2.07
History of streptomycin for TB
treatment
3.49 1.52–8.02
Referring site Outpatient facility Referent
Inpatient facility 1.11 0.74–1.70
Sex Female Referent
Male 0.83 0.57–1.22
Smear microscopy Sputum smear negative or not
reported
Referent
Sputum smear positive
(scanty or higher)
1.00 0.69–1.47
Presenting
symptom
No cough Referent
Any cough 1.37 0.90–2.08
Co-morbiditiesb No reported pre-existing renal
insufficiency, liver or psychiatric
disorder
Referent
Pre-existing renal, liver, or
psychiatric condition
0.47 0.11–1.93
Bolded values are statistically significant at p-value < 0.05
ART antiretroviral therapy, RR TB rifampicin resistant tuberculosis, sHR
subdistribution hazard ratio
asHR crude analysis from competing risk regression accounting for death and
loss from treatment
bNo pregnant women had a documented severe AE prior to censoring
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contributed 52,684 person-days of follow-up with a me-
dian exposure of 70 days (IQR: 28, 183) from treatment
initiation until severe AE or censoring. Of the 560, 268
(47.9 %) completed 6 months of treatment, 171 (30.5 %)
were followed until transferred to another site, 73
(13.0 %) were lost from treatment, and 48 (8.6 %) died.
There were 107 severe AEs analysed, giving an incidence
rate for severe AE of 0.74 per person year.
HIV-positive patients with low CD4 counts (≤100
cells/mm3) and those who initiated ART with RR TB
treatment both were approximately 3 times more likely
to experience a severe AE with crude sHR: 2.76 (95 %
CI: 1.30–5.84) and sHR: 3.07 (95 % CI: 1.46–6.46), re-
spectively (Table 3). Patients previously treated for TB
with a regimen including streptomycin were also more
likely to experience a severe AE, sHR: 3.49 (95 % CI:
1.52–8.02), all were ototoxicity. Subdistribution hazard
ratios for categorized age, low weight at treatment initi-
ation, smear microscopy positive, recent hospitalization,
sex, cough at initiation, or pre-existing renal, liver, or
psychiatric conditions were not statistically different.
Competing risk regression sHR can be displayed as a
graph of the cumulative incidence (of the risk analysed)
function over the time at risk. Figure 3 shows patients
initiating ART with or after RR TB treatment had thehighest sHR of experiencing a severe AE versus HIV-
negative patients, HIV-positive patients who had been
on ART prior to RR TB diagnosis, and HIV-positive pa-
tients never on ART. As a comparison, the cumulative
incidence function of death during RR TB treatment, ac-
counting for the competing risk of loss from treatment,
is shown for the same HIV and ART categories (Fig. 4).
HIV-positive patients who did not initiate ART either be-
fore or at RR TB initiation were more than 3 times more
likely to die during RR TB treatment than HIV-negative
patients (sHR: 3.25, 95 % CI: 1.17–9.02). Figure 4 shows
Fig. 3 Cumulative incidence function after competing risk regression of any severe adverse event. Legend: Competing risk accounting for loss
from treatment and death during treatment, by HIV and ART status
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second-line TB treatment was highest for HIV-positive pa-
tients never on ART versus HIV-negative, HIV-positive
patients who had been on ART prior to RR TB diagnosis,
and HIV-positive patients initiating ART along with or
after RR TB treatment.
Discussion
During the first six months of RR TB treatment in a
context where 82.5 % of patients were also infected with
HIV, 35.3 % of patients experienced at least 1 AE. This
incidence was less than reported in a meta-analysis ofFig. 4 Cumulative incidence function after competing risk regression of de
loss from treatment, by HIV and ART statusadverse drug events during the 18 to 24 months of treat-
ment of MDR-TB, which found 57.3 % of patients (260/
534) experienced at least one AE [6]. One of the in-
cluded studies, from a similar context in South Africa,
reported that 99 % of the 71 patients in that cohort ex-
perienced at least one AE [17]. The meta-analysis did
not report whether the AEs were mild, moderate, severe,
life threatening, or fatal [6]. In our cohort, the incidence
of severe AEs during the first 6 months of treatment was
19.0 %, far higher than the 6.9 % reported in a large co-
hort of HIV positive, ART naïve MDR TB patients also
from South Africa [18].ath during RR TB treatment. Legend: Competing risk accounting for
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or severe AE for 54.4 % of cohort patients experiencing an
AE. Kanamycin, along with other aminoglycosides, is asso-
ciated with ototoxicity (hearing loss and vestibular dys-
function) and renal dysfunction [4, 13, 18, 19]. While an
effective agent against drug-resistant TB [9], multiple trials
are underway to develop an injection-free regimen for
treating RR TB in an attempt to reduce the overall burden
of ADR and improve adherence to long-term therapy [20].
Our finding that patients recently initiating both ART
and RR TB treatment have an increased sHR for severe
AE during the first 6 months (sHR: 3.07) has not been
previously reported. The WHO recommendation to im-
mediately initiate ART was based upon lower risk of death
but found that there was ‘very low quality of evidence’ as
to whether concomitant use of ART and RR TB treatment
led to more severe AE or drug interactions [9]. A previous
systematic review of the use of ART during second-line
TB treatment concluded there was insufficient data as to
whether concomitant use of ART and RR TB treatment
increased the risk of ADR [8]. A study of XDR TB patients
in South Africa found that there was no difference in the
proportion of patients (using chi-squared test) with a se-
vere AE reported for HIV-positive patients on ART com-
pared to HIV-negative patients [21]. Our finding of the
higher sHR for severe AE may be because other studies
did not differentiate the grade of AE, had insufficient
numbers of patients on ART, or did not differentiate the
time on ART. Additionally, using the competing risk
methodology to calculate sHR accounting for the compet-
ing risk of death and loss from treatment was useful in the
context of very high early mortality for patients not on
ART. The increased sHR point to a need for additional or
more frequent monitoring for AE for patients initiating
both ART and RR TB treatment at the same time. These
patients may also benefit from inpatient treatment initi-
ation where they can be more closely monitored and
managed.
The cumulative incidence function for mortality ac-
counting for the competing risk of loss to treatment in-
dicated that patients not on ART are most at risk of
death and therefore our results are consistent with
studies and guidelines that indicate early initiation of
ART for patients with TB [22–24] and drug-resistant
TB [8, 9]. This reversal of risk (patients with highest
relative sHR of mortality have the lowest relative sHR
of severe AE) also highlights the need for greater access
to ART and initiation at higher CD4 counts. In our study,
there was a high proportion of patients with very low CD4
counts not on ART despite increasing access to ARVs in
South Africa; patients with CD4 ≤ 100 cells/mm3 also had
a higher sHR of severe AE (sHR: 2.76). Further, a quarter
of the patient files reviewed in this study were diagnosed
with RR TB while hospitalized although testing for RIFresistance is available at the lowest levels of the public
health system in South Africa. Again, this represents de-
lays in diagnosis and case finding at the primary health
care level leading to hospitalization and late diagnoses.
While most nausea and vomiting were reported as
mild to moderate (67.1 % of 70 reports) this AE can im-
pact on both adherence and effectiveness of treatment.
Because of AEs, the treating clinicians discontinued or
reduced the dosage of the suspected drug for 17.3 % of
patients (100/578), a similar proportion to the 21 % cal-
culated from a patient-level meta-analysis of MDR-TB
studies [25]. Because of overlapping toxicities, a patient
who experienced an AE during RR TB treatment may no
longer be eligible for standard ART or second-line TB
treatment regimens, for example because of drug-
induced liver or kidney injuries. Having fewer effective
drugs in the second-line TB regimen is associated with
lower probability of treatment success [25] and conse-
quently higher risk of acquired additional resistance.
Prior exposure to streptomycin may be a risk factor
for ototoxicity during RR TB treatment with increased
aminoglycoside cumulative dose [13]. In our cohort, al-
though the numbers of patients with prior exposure
were small (1.2 %), this was the strongest predictor of a
severe AE (sHR: 3.30), with all severe AEs related to oto-
toxicity. With the introduction of Xpert MTB/RIF diag-
nosis, the ‘retreatment’ regimen containing streptomycin
was phased out and as of end 2013 is no longer in use in
the South African NTP [26]. While the lack of history of
prior TB treatment may reduce the risk of some types of
ADR, from a public health perspective the 76.0 % of pa-
tients in this cohort without any prior TB history is con-
cerning as it indicates primary transmission of RR TB.
Limitations
The lower rates of ADR in this cohort may be a result of
both the lack of routine reporting and retrospective
study design. During the monthly visits to the outpatient
clinic, patients are not prompted to self-report AE. In
some cases, patients may have discussed AE with the
counsellor, nurse, or clinician but if the healthcare
worker did not note the discussion in the medical file it
would not have been counted in this review. This may
have resulted in an under-reporting of AEs, particularly
those that were mild to moderate (grade 1-2). Con-
versely, clinicians may have spent more time monitoring
or documenting AEs for patients who initiated treatment
in poor clinical condition (e.g. hospitalized or concur-
rently starting on ART) compared to patients who were
clinically stable.
Also, while guidelines indicate monitoring for certain
AEs, implementation may differ from intended practice.
One challenge that both sites noted during out study
was that it was difficult to access audiology screening for
Schnippel et al. BMC Infectious Diseases  (2016) 16:593 Page 9 of 10patients due to concerns about infection control as audi-
ology services were not co-located within the TB clinic.
Additionally, our study focused on the first 6 months of
treatment, the intensive phase, which includes kanamy-
cin. It is possible that some patients who did not experi-
ence an ADR during the first 6 months would be
affected in subsequent months or that an ADR would be
detected in subsequent months, specifically aminoglyco-
side ototoxicity is known to occur even after treatment
discontinuation [27].
Another limitation of this study was the inability to
distinguish between the AE and ADR. For this reason,
events described in this analysis were described as AE
rather than the more specific term ADR. This limitation
is common to studies describing ADR and AE and must
be taken into consideration when trying to draw conclu-
sions across studies. For example, in the South African
study indicated above with 99 % incidence of AE, injec-
tion site pain was the second most commonly reported
clinical AE. Injection site pain was only reported in this
cohort for patients refusing to continue with the injec-
tions for reason of pain. Deaths were only included in
the analysis if the clinician indicated that the death was
likely due to an ADR; it is possible that deaths from
ADR are underestimated as a result. Cause of death, par-
ticularly for outpatient care, are often not available as
the patients die at home or in a different facility. This
study also did not try to distinguish whether the AE was
related to the ART or second-line TB treatment.
Finally, the study period preceded the roll-out of beda-
quiline and linezolid in the South African NTP. These
two drugs are now available for patients who experience
toxicity to one of the drugs of the standard regimen [28]
and use of the new and re-purposed drugs may affect
the profile of ADR experienced by patients with drug-
resistant TB in South Africa.
Conclusions
Severe adverse events are common during the first
6 months of second-line treatment and HIV-positive pa-
tients newly initiating ART have the highest relative sub-
distribution hazard ratio of experiencing a severe AE,
accounting for the competing risk of death and loss from
treatment. Patients whose clinical condition requires im-
mediate and concomitant initiation of ART and RR TB
treatment may benefit from new RR TB treatment regi-
mens that are better tolerated, intensive monitoring, or
even inpatient treatment initially to watch for severe AEs.
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